Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age

Aging Clinical Trial

— Nitrite  

Official title:

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04405180
• Other study ID #: STUDY20110334
• Secondary ID: R01AG058883
• Status: Completed
• Phase: Phase 2
• Start date: April 23, 2021
• Est. completion date: July 14, 2023

Study information

• Verified date: December 2023
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This 2-site randomized double blinded controlled trial is to confirm and more definitively clarify the impact of a 12-week course of nitrite versus placebo on mitochondrial bioenergetics in older sedentary adults. This investigator will take an integrative physiology approach to determine the effect of nitrite therapy on a comprehensive assessment of mitochondrial energetics, skeletal muscle vascular function, and whole body physical function (cardiorespiratory function, exercise endurance, strength, balance, and physical activity) and fatigability.

Description:

Old age is associated with declining skeletal muscle mitochondrial bioenergetics with related decrements in cardiorespiratory fitness (CRF) and physical function that predispose to frailty, disability, and diminished quality of life. While exercise training may moderate and possibly even reverse declines in mitochondrial bioenergetics, potential for such benefit is typically confounded by exercise intolerance with early fatigability that results from the same age-related mitochondrial declines. Consequently, sedentariness is endemic and insidious among the growing population of older adults. This trial is to study the utility of inorganic nitrite salts as a novel means to modify this detrimental pattern. Classic studies demonstrate that nitrite facilitates hypoxic vasodilation in muscle. This investigator's preliminary data suggests that nitrite treatment also augments skeletal muscle mitochondrial bioenergetics in older adults. This investigator proposes improving mitochondrial function will also be reflected in clinical parameters, including CRF as well as broader functional attributes (endurance, strength, and balance) that enable physical activity (PA) and opportunity to mitigate frailty and disability. As such, this application is in line with the National Institute on Aging's mission to develop targeted interventions to prevent and treat age-associated conditions. This multi-disciplinary team has published seminal work indicating that mitochondrial bioenergetics and CRF are significant determinants of physical function in older adults. In parallel efforts, this investigative team showed efficacy of chronic nitrite therapy to improve mitochondrial bioenergetics in older sedentary adults. Only one month of nitrite therapy significantly improved ex vivo assessments of mitochondrial energetics in skeletal muscle biopsies, concomitant with increased skeletal muscle sirtuin-3 expression, a nicotinamide adenine dinucleotide (NAD) dependent lysine deacetylase and key regulator of mitochondrial metabolism. These key data reinforce the premise that nitrite enhances vital mitochondrial metabolism in older adults. Moreover, improvement in muscle energetics in nitrite-treated older adults was linked with increased exercise efficiency as evidenced by reduced oxygen consumption (VO2) during submaximal steady-state walking. This data supports the hypothesis that nitrite will make physical function easier such that physical activity will increase.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: July 14, 2023
• Est. primary completion date: July 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Age =70 years

• Sedentary (<1 hour/week of volitional exercise activity)

• Clinically stable (euvolemic; baseline HR <100 bpm) and without hospitalization or invasive cardiac procedure for 6 weeks

Exclusion Criteria:

• Blood pressure <110 or >160/95 mmHg

• Orthopedic or other chronic condition which limits physical activity or exercise testing assessments

• If valve replacement has been performed, patient may not be enrolled for 12 months after this procedure

• Severe peripheral or pulmonary artery disease

• Anemia: Hgb <11.0 (?),10.0 (?) gm/dl

• Participants with diabetes whose HgbA1c >10.0%

• Chronic alcohol (>14 drinks ETOH a week) or drug (any cocaine, methamphetamine, and cannabis =4 x week) dependency

• Allergy to lidocaine and red dye

• Chronic use of oral corticosteroids or other medications that affect muscle function

• Current use of organic nitrates or phosphodiesterase type 5 (PDE5) inhibitors

• Unable to hold warfarin, direct-acting oral anticoagulants (DOACs), non-steroidal anti-inflammatory medications (NSAIDs) or aspirin for 3 days prior to muscle biopsy, or to hold thienopyridine medications for 5 days prior to muscle biopsy. Participants unable or unwilling to hold will follow the modified ASA hold plan

• Any bleeding disorder that would contraindicate biopsy such as history of clinically significant bleeding diathesis (e.g., Hemophilia A or B, Von Willebrand's Disease or congenital Factor VII deficiency)

• Unstable psychiatric diagnosis that would affect adherence and ability to complete the protocol

• Dementia or inability to give informed consent or follow study protocol

• End-stage disease

• Other chronic unstable disease such as active neoplasm, end stage chronic kidney, liver or other organ disease

Related Conditions & MeSH terms

• Aging
• Frailty
• Sedentary Lifestyle

Intervention

Drug:
• Placebos
Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
• 20mg sodium nitrite tid
Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.

Locations

Country	Name	City	State
United States	University Of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Gladwin, Mark, MD	National Institute on Aging (NIA), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Baseline to 12-week change in Peak oxygen uptake (VO2) achieved during progressive resistance exercise testing	We will measure changes in cardiorespiratory fitness including Peak oxygen uptake (VO2) achieved during progressive resistance exercise testing (Increased VO2 notes increased oxygen uptake).; These will be assessed before and after 12 weeks (16 weeks total) of oral inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Other	Baseline to 12-week change in VO2 during steady state exercise	We will measure changes in cardiorespiratory fitness including VO2 during steady state exercise (Increased VO2 notes increased oxygen uptake).; These will be assessed before and after 12 weeks (16 weeks total) of oral inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Other	Baseline to 12-week change in duration of constant work rate exercise	We will measure changes in cardiorespiratory fitness including duration of constant work rate exercise (longer times denote increased exercise capacity).; These will be assessed before and after 12 weeks (16 weeks total) of oral inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Other	Baseline to 12-week change in time of 400 m corridor walking	We will measure changes in cardiorespiratory fitness including time of 400 m corridor walking (decreased time denote increased exercise capacity).; These will be assessed before and after 12 weeks (16 weeks total) of oral inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Other	Baseline to 12-week change in fatiguability during Steady State walking	Using the Borg Rating of Perceived Exertion (units 6-20), we will measure how much fatiguing the steady-state walking test (at 1.5 mph) is to the participant. We will compare this to the RPE of this test again after 12-weeks (up to 16-weeks) of inorganic nitrite supplementation vs placebo. Lower RPE notes improvement.	12-week course of study drug supplementation, up to 16 weeks total
Other	Short Physical Performance Battery, Baseline to 12-week change	Will assess SPPB Score and its change after 12-weeks (up to 16-weeks) of inorganic nitrite supplementation vs placebo. Higher score shows improvement.	12-week course of study drug supplementation, up to 16 weeks total
Other	Handgrip Strength, Baseline to 12-week change	Will assess handgrip strength in the dominant hand, and its change after 12-weeks (up to 16-weeks) of inorganic nitrite supplementation vs placebo. Higher score shows improvement.	12-week course of study drug supplementation, up to 16 weeks total
Other	Steps - Physical activity (accelerometry)	Using an Actigraph accelerometry device on the participant's wrist, will assess daily steps and its change with 12-weeks (up to 16-weeks) of inorganic nitrite supplementation vs placebo. Higher number of steps note improvement.	12-week course of study drug supplementation, up to 16 weeks total
Other	Vector Magnitude Counts - Physical activity (accelerometry)	Using an Actigraph accelerometry device on the participant's wrist, will assess daily vector magnitude counts and its change with 12-weeks (up to 16-weeks) of inorganic nitrite supplementation vs placebo. Higher number of counts note improvement.	12-week course of study drug supplementation, up to 16 weeks total
Primary	Skeletal muscle mitochondrial respiration State 3, Baseline to 12-week change	We will use high resolution respirometry via Oroboros Oxygraph 2k to assess the effects of 12 weeks of inorganic nitrite vs placebo on skeletal muscle mitochondrial respiration from samples obtained via vastus lateralis muscle biopsy.	12-week course of study drug supplementation, up to 16 weeks total
Secondary	Skeletal Muscle adenosine triphosphate (ATP) production, Baseline to 12-week change	Using phosphorus-magnetic resonance spectroscopy, we will measure ATP production and how it will change after 12 weeks (up to 16 weeks) of inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Secondary	Change in cross-sectional area for each fiber type by skeletal muscle microscopy, Baseline to 12-week change	Using microscopy and immmunofluorescence, we will measure the cross-sectional area for each fiber type, relative fiber type number, and relative area composition of each muscle fiber type and mitochondrial content (area/section) after 12 weeks of inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Secondary	Change in relative fiber type number by skeletal muscle microscopy, Baseline to 12-week change	Using microscopy and immmunofluorescence, we will measure the cross-sectional area for each fiber type, relative fiber type number, and relative area composition of each muscle fiber type and mitochondrial content (area/section) after 12 weeks of inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Secondary	Change in relative area composition of each muscle fiber type by skeletal muscle microscopy, Baseline to 12-week change	Using microscopy and immmunofluorescence, we will measure the cross-sectional area for each fiber type, relative fiber type number, and relative area composition of each muscle fiber type and mitochondrial content (area/section) after 12 weeks of inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total
Secondary	Change in mitochondrial content (area/section) by skeletal muscle microscopy, Baseline to 12-week change	Using microscopy and immmunofluorescence, we will measure the cross-sectional area for each fiber type, relative fiber type number, and relative area composition of each muscle fiber type and mitochondrial content (area/section) after 12 weeks of inorganic nitrite supplementation vs placebo.	12-week course of study drug supplementation, up to 16 weeks total